PCL, Inc.

Equities

A241820

KR7241820000

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1,201 ^KRW	-0.25%		-1.40%	-66.50%

Jan. 16	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	CI
2023	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	CI

PCL, Inc. announced that it expects to receive KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.

December 20, 2022

PCL, Inc. announced a private placement of 224,483 common shares having face value of KRW 500 per share, at an issue price of KRW 13,364 per share for the gross proceeds of KRW 2,999,990,812 on December 21, 2022. The transaction will include participation from new investor Hyeopsim Co ., Ltd. The transaction has been approved by board of directors of the company. The common shares will be allotted through third-party allotment method.

The transaction is expected to close on December 29, 2022. All the securities issued in the transaction will subject to a hold period of one year.

Latest news about PCL, Inc.

PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	Jan. 15	CI
PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	Dec. 25	CI
PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	Dec. 20	CI
PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from Global Emerging Markets	Dec. 14	CI
South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	23-05-31	MT
PCL to Raise 36 Billion Won via Share Issuance	23-05-31	MT
PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	22-12-28	CI
PCL to Raise 3 Billion Won via Share Issuance; Shares Jump 4%	22-12-21	MT
PCL, Inc. announced that it expects to receive KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	22-12-20	CI
PCL, Inc. terminated the acquisition of 40.76% stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd.	22-12-11	CI
PCL, Inc. announced that it has received KRW 12.060247575 billion in funding	22-12-11	CI
OliX Pharmaceuticals, Inc agreed to acquire 6.63% stake in PCL, Inc. for KRW8.04 billion.	22-11-10	CI
PCL, Inc. agreed to acquire unknown minority stake in stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd. for KRW12.2 billion.	22-11-10	CI
PCL, Inc.(KOSDAQ:A241820) dropped from S&P Global BMI Index	22-04-07	CI
PCL, Inc.(KOSDAQ:A241820) added to S&P Global BMI Index	21-09-20	CI
MCureX Therapeutics, Inc. announced that it expects to receive KRW 2 billion in funding from OliX Pharmaceuticals,Inc, PCL, Inc., Samyang Holdings Corporation	21-06-22	CI
PCL, Inc. announced that it has received KRW 40.499938368 billion in funding from a group of investors	21-03-24	CI
Datametrex AI Limited Secures Authorization by Health Canada for PCL Inc.'s COVID19 Rapid Antigen Test Kit	21-03-23	CI
PCL, Inc. announced that it expects to receive KRW 40.499938368 billion in funding from a group of investors	21-03-17	CI
Datametrex AI Limited Announces Submission of a Medical Devices Interim Order Request Form to Approve PCL, Inc.’s COV05 COVID19 Rapid Antigen Detection Kits to Health Canada	20-09-01	CI
Datametrex AI Limited Secures Rights to Sell and Distribute Pcl, Inc.’s COV05 COVID19 Rapid Antigen Detection Kits	20-08-12	CI
PCL, Inc. announced that it has received KRW 9.999993558 billion in funding from Korea Investment Partners Co. Ltd.	19-10-30	CI
PCL, Inc. announced that it expects to receive KRW 9.999993558 billion in funding from Korea Investment Partners Co. Ltd.	19-10-22	CI
PCL, Inc. has completed an IPO in the amount of KRW 12 billion.	17-02-17	CI

Chart PCL, Inc.

Duration

Period

More charts

Company Profile

PCL Inc. is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Companyâs products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
PCL, INC.	-66.50%	47.15M
EXACT SCIENCES CORPORATION	-20.45%	10.82B
IOVANCE BIOTHERAPEUTICS, INC.	+43.17%	3.25B
GUARDANT HEALTH, INC.	-35.86%	2.11B
BGI GENOMICS CO., LTD.	-17.21%	2.08B
VERACYTE, INC.	-29.81%	1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+17.56%	1.02B
SEEGENE, INC.	-4.37%	733M
CAREDX, INC	-37.00%	391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.94%	377M

Bio Diagnostics & Testing